The agreement is slated to lay a foundation for Nuvisan to establish the Berlin-based research unit and support Bayer’s focus on the flexibility and productivity of its research & development operating model, according to a news release.
Nuvisan is a company that provides services for clinical studies, laboratory services and contract manufacturing at multiple sites in Germany and France. Its new Berlin unit consists of about 400 workplaces with a fully operational team specializing in small molecule research. The research center includes capabilities and capacities across the drug discovery value chain.
Bayer plans to retain significant research activities in Berlin, the city which headquarters its pharmaceuticals division, along with one of its major global research sites. It also intends to cooperate with Nuvisan to build the new research center in Berlin, with the transaction expected to close sometime in mid-2020.
“With Nuvisan we have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists,” Bayer pharmaceuticals division executive committee member & head of R&D Dr. Joerg Moeller said in the news release. “Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists.”
Nuvisan CEO & managing partner Dietrich Bruchmann said the company will not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology.
“The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials,” Bruchmann said.